anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background and Objectives: Long-term outcomes of immediately postoperative rotational malreduction in the axial plane after operative treatment of supracondylar humeral fractures (SCHF) are unknown. This study aimed to investigate the long-term clinical outcomes and associated factors for immediately postoperative rotational malreduction of SCHF. Materials and methods: In this retrospective case-control study, 88 patients who underwent surgery for Gratland type III SCHF were enrolled between January 2012 and January 2020. Among them, 49 patients had immediately postoperative malrotational reduction (rotational malreduction group) and 39 patients had no rotational deformity (control group). To evaluate the associated factors for immediately postoperative rotational malreduction, demographic data, fracture patterns, physical examination signs, and preoperative radiological parameters were analyzed. To compare the clinical outcomes, operation time, range of motion of the elbow, time from operation to full range of motion, and Flynn criteria were evaluated. The Oxford elbow score was used to investigate long-term clinical outcomes for patients five years after operation. Results: The mean age was 5.7 ± 2.3 years and mean follow-up period was 15.7 ± 4.0 months. The rotational malreduction group had significantly more patients with oblique fracture pattern (p = 0.031) and Pucker sign (p = 0.016) and showed a significantly longer operative time (p = 0.029) than the control group. Although there was no significant difference in the range of elbow motion and the Flynn criteria, the Kaplan-Meier survival curve showed a longer time to recover the full range of elbow motion in the rotational malreduction group (p = 0.040). There were no significant differences in the long-term clinical outcomes assessed using the Oxford elbow score (p = 0.684). Conclusions: Oblique fracture pattern and Pucker sign may be associated with immediately postoperative rotational malreduction in the axial plane. Although patients with immediately postoperative rotational malreduction showed favorable results of long-term clinical outcomes, they required more weeks to recover the full range of elbow motion.
LORTAB ELIXIR contains hydrocodone, a Schedule II controlled substance. As an opioid, LORTAB ELIXIR exposes users to the risks of addiction, abuse, and misuse [see DRUG ABUSE AND DEPENDENCE]. 

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed LORTAB ELIXIR. Addiction can occur at recommended dosages and if the drug is misused or abused. 

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing LORTAB ELIXIR, and monitor all patients receiving LORTAB ELIXIR for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as LORTAB ELIXIR, but use in such patients necessitates intensive counseling about the risks and proper use of LORTAB ELIXIR along with intensive monitoring for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see WARNINGS; Life-Threatening Respiratory Depression, DOSAGE AND ADMINISTRATION; Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose]. 

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing LORTAB ELIXIR. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see PRECAUTIONS; Information for Patients/Caregivers]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
Methods for increasing RRR-alpha-tocopherol in the tissues of a pre-pregnant, pregnant, or lactating woman are disclosed. The woman is administered a nutritional supplement containing a blend of alpha tocopherols comprising RRR-alpha-tocopherol and non-RRR-alpha-tocopherol. The blend of alpha tocopherols has a weight ratio of RRR-alpha-tocopherol to non-RRR-alpha-tocopherol between about 0.5:1 to about 1,000:1. Methods for increasing RRR-alpha-tocopherol for a fetus are also disclosed, where the fetus receives increased RRR-alpha-tocopherol from a pregnant woman who is administered a prenatal nutritional supplement containing a blend of alpha-tocopherols with a weight ratio of RRR-alpha-tocopherol to non-RRR-alpha-tocopherol between about 0.5:1 to about 1,000:1. Methods for increasing RRR-alpha-tocopherol for a breast milk-fed infant are also disclosed, where the infant receives increased RRR-alpha-tocopherol from the breast milk of a pregnant woman who is administered a postpartum nutritional supplement containing a blend of alpha-tocopherols with a weight ratio of RRR-alpha-tocopherol to non-RRR-alpha-tocopherol between about 0.5:1 to about 1,000:1. These methods provide the woman's body with increased RRR-alpha-tocopherol, which is then preferentially available to her developing fetus or nursing infant.
PURPOSE:To provide a cholesterol-reducing agent containing grifolin and/or neogrifolin as active ingredients. CONSTITUTION:The cholesterol-reducing agent contains grifolin and/or neogrifolin as active ingredients. The grifolin and the neogrifolin have the excellent cholesterol-reducing actions for plasma cholesterol and hepatic cholesterol, especially the excellent action for low density lipoprotein cholesterol. The grifolin and the neogrifolin are isolated e.g. by extracting a mushroom, e.g. NINGYOUTAKE (a kind of mushroom), belonging to the genus Albatrellus with an organic solvent and subsequently subjecting the extract to column chromatography for fractionation. The cholesterol is accumulated on arterial walls and becomes a factor for stimulating arteriosclerosis, when excessively contained in a body, and hypertension, cerebral hemorrhage, etc., caused by the arteriosclerosis are troublesome as the diseases of aged people.
INTRODUCTION: Many individuals start dialysis in an acute setting with suboptimal pre-dialysis education. These individuals are often treated with central venous catheter insertion and initiation of in-center hemodialysis and only a minority will transfer to a home-based therapy. The dialysis start unit is a program performing in-center hemodialysis in a separate space while providing support and education on chronic kidney disease and treatment options in the initial weeks of kidney replacement therapy. We aimed to assess the uptake of home dialysis therapies between 2013 and 2021 among patients who started acute inpatient hemodialysis at University Health Network, Toronto and underwent dialysis at the dialysis start unit.
METHODS: This is a retrospective observational cohort study based on prospectively collected data. Patients' demographics were obtained from electronic charts. In the dialysis start unit, all patients received dialysis modality education by a nurse educator, dedicated home dialysis nurses, and the allied health care team.
FINDINGS: During 2013-2021, 122 patients were dialyzed in the dialysis start unit and included in the study. Among those patients, 68 patients ultimately chose home dialysis (57 peritoneal dialysis and 11 home hemodialysis). Fifty-four patients continued in-center hemodialysis. Patients adopting home dialysis were less likely to have diabetes and hypertension as the etiology of kidney failure and more likely to have glomerulonephritis or vasculitis.
DISCUSSION: Dialysis modality education is implementable in advanced chronic kidney disease. Individualized education and care after unplanned start dialysis can potentially enhance home dialysis choice and utilization.
Varenicline tablets contain varenicline (as the tartrate salt), which is a partial nicotinic agonist selective for α4β2 nicotinic acetylcholine receptor subtypes.

Varenicline, as the tartrate salt of maltodextrin premix (1:1:10), is a powder which is a off-white to pinkish brown color with the following chemical name: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3- h][3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate with maltodextrin (1:1:10). It is soluble in water, practically insoluble in acetone and methylene dichloride. Varenicline tartrate has a molecular weight of 361.35 Daltons and maltodextrin, and a molecular formula of C13H13N3 • C4H6O6 and maltodextrin. The chemical structure is:

Varenicline tablets are supplied for oral administration in two strengths: a 0.5 mg circular, biconvex, white to off-white film-coated tablets, debossed with “P” on one side and “155” on other side and a 1 mg circular, biconvex, light blue film-coated tablets, debossed with “P” on one side and “156” on other side. Each 0.5 mg varenicline tablet contains 0.85 mg of varenicline tartrate equivalent to 0.5 mg of varenicline free base; each 1 mg varenicline tablet contains 1.71 mg of varenicline tartrate equivalent to 1 mg of varenicline free base. The following inactive ingredients are included in the tablets: croscarmellose sodium, maltodextrin, microcrystalline cellulose, stearic acid. The tablets are film-coated with a coating material containing hydroxypropyl cellulose, hypromellose, talc, and titanium dioxide. In addition to these, the 1 mg tablet film coating includes FD&C blue #2/indigo carmine aluminum lake and iron oxide yellow.
In recent decades, the prevalence of obesity has risen dramatically worldwide, presenting significant public health concerns. Beyond its metabolic implications, obesity profoundly impacts sexual health, particularly in males, with erectile dysfunction (ED) emerging as a prevalent and distressing comorbidity. Obesity exacerbates the risk of ED through complex interplays of physiological and psychological mechanisms. Physiologically, excess adiposity leads to chronic inflammation, endothelial dysfunction, and hormonal imbalances, all of which contribute to impaired vascular health and reduced testosterone levels, key factors in erectile function. Psychologically, body image dissatisfaction and decreased self-esteem associated with obesity can exacerbate sexual performance anxiety and further contribute to ED. Bariatric surgery is an established treatment method for long-term weight loss which also alleviates symptoms of diabetes, hypertension, and other weight-related comorbidities.
Methods and devices and systems include generating analyte data based on signals from an analyte sensor transcutaneously positioned in contact with interstitial fluid under a skin layer of a user and to generate signals corresponding to an analyte level of a target analyte. The analyte data corresponds to the analyte level of the target analyte over a wear period. Methods include storing the analyte data over the wear period. Methods include determining one or more indications based on the analyte data. Methods include determining a reimbursement insurance code based at least in part on stored sensor information associated with the analyte sensor. Methods include communicating at least a portion of the analyte data and the reimbursement insurance code to an electronic record associated with the user and stored by a remote electronic medical record system. Methods include providing the one or more indications on a user interface unit.
A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
The present invention provides an oligopeptide compound with an amino acid sequence of Tyr-Leu-Val-Leu-His (SEQ ID NO:1) and HIV-1 protease inhibitory activity. The oligopeptide compound provided by the invention can be produced from chemical synthesis, or recombination, or microorganism (particularly actinomycetes) extraction. The invention also provides an extract obtained from microorganism (particularly actinomycetes) and having HIV-1 protease inhibitory activity and a preparation method thereof. The extract contains the oligopeptide compound provided by the invention. The invention also provides microorganisms (particularly actinomycetes, such as Actinomyces CGMCC 4766) for obtaining the oligopeptide compound or extract provided by the invention. The oligopeptide compound or extract provided by the invention can be used for prevention and treatment of HIV infection related diseases, such as AIDS.
BACKGROUND: Obstructive sleep apnea is associated with COVID-19 infection. Less clear is whether obstructive sleep apnea is a risk factor for the development of post-acute sequelae of SARS-CoV-2 infection (PASC).
STUDY DESIGN: Cross-sectional survey of a general population of 24,803 US adults to determine the association of obstructive sleep apnea with PASC.
RESULTS: COVID-19 infection occurred in 10,324 (41.6%) participants. Prevalence of persistent (>3 months post infection) putative PASC-related physical and mental health symptoms ranged from 6.5% (peripheral edema) to 19.6% (nervous/anxious). In logistic regression models, obstructive sleep apnea was associated with all putative PASC-related symptoms with the highest adjusted odds ratios being fever (2.053) and nervous/anxious (1.939). In 4 logistic regression models of overall PASC derived from elastic net regression, obstructive sleep apnea was associated with PASC (range of adjusted odds ratios: 1.934-2.071); this association was mitigated in those with treated obstructive sleep apnea. In the best fitting overall model requiring ≥3 symptoms, PASC prevalence was 21.9%.
CONCLUSION: In a general population sample, obstructive sleep apnea is associated with the development of PASC-related symptoms and a global definition of PASC. Treated obstructive sleep apnea mitigates the latter risk. The presence of 3 or more PASC symptoms may be useful in identifying cases and for future research.
PROBLEM TO BE SOLVED: To develop a utilization method for an astringent coat, etc., of chestnut which has hitherto been almost completely discarded except for the use in folk medicine and to facilitate the wide utilization of the coat as a bathing agent. SOLUTION: Chestnut flour is produced by pulverizing well-dried astringent coat and shell of chestnut with a mill and roasting the powder. Separately, SAKE (Japanese rice wine) lees is dried with cold air and pulverized to produce SAKE lees powder. The chestnut flour is mixed with the SAKE lees powder at a ratio of 7:3, thoroughly mixed and put into a tea-bag to obtain the objective powdery bathing agent. A liquid bathing agent consisting of a concentrated extract can be produced by putting 30 g of the powdery bathing agent into a vessel containing 1,000cc of fresh water and boiling and decocting the mixture. The tea-bag is dipped in the bathing water or the concentrated extract is dropped into the bathing water.
Pharmaceutically-acceptable compositions containing, as an active ingredient, at least one N-acylanilinobutyric acid have uses unrelated to the choleretic activity suggested in U.S. Pat. No. 3,780,095. Moreover, the further uses generally involve administration of smaller doses than would be required to obtain a choleretic effect. 
     The new uses include: (a) increasing the gastrointestinal enzyme secretion and (b) tonicizing the cardiovascular system. The increase of the gastrointestinal enzyme secretion is applied in the treatment of different diseases, such as treatment of sprue, treatment of indigestion, treatment of acute and chronic pancreatitis, therapy for degenerated intestine mucous membrane, treatment of stomach spasms, treatment of stomach ulcers, treatment of diseases where the application of an antigastrin is indicated. The tonicising of the cardiovascular system is applied in, e.g., increasing the circulation of blood in internal organs, increasing the heart force, treating disturbances in the liver function.
Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al. (Samuel-Hodge, Carmen D., et al. "Randomized Trial of a Behavioral Weight Loss Intervention for Low?income Women: The Weight Wise Program." Obesity 17.10 (2009): 1891-1899). The only modifications to the content (other than some general formatting) will be the combining of sessions 3 and 4 and sessions 6 and 7. These changes will allow us to fit the original 16-session curriculum into the 14-session format of our intervention.
Development of functional recovery therapies is critical to reduce the global impact of stroke as the leading cause of long-term disability. Our previous studies found that acute-phase protein orosomucoid (ORM) could provide an up to 6 h therapeutic time window to reduce infarct volume in acute ischemic stroke by improving endothelial function. However, its role in neurons and functional recovery post-stroke remains largely unknown. Here, we showed that exogenous ORM administration with initial injection at 0.5 h (early) or 12 h (delayed) post-MCAO daily for consecutive 7 days significantly decreased infarct area, improved motor and cognitive functional recovery, and promoted mitochondrial biogenesis after MCAO. While neuron-specific knockout of ORM2, a dominant subtype of ORM in the brain, produced opposite effects which could be rescued by exogenous ORM. In vitro, exogenous ORM protected SH-SY5Y cells from OGD-induced damage and promoted mitochondrial biogenesis, while endogenous ORM2 deficiency worsened these processes. Mechanistically, inactivation of CCR5 or AMPK eliminated the protective effects of ORM on neuronal damage and mitochondrial biogenesis. Taken together, our findings demonstrate that ORM, mainly ORM2, is an endogenous regulator of neuronal mitochondrial biogenesis by activating CCR5/AMPK signaling pathway, and might act as a potential therapeutic target for the functional recovery post-stroke.
Human Normal Immunoglobulin for Subcutaneous Administration (Octanorm) is a liquid formulation of normal human IgG at a concentration of 16.5% administered as a SC infusion at weekly intervals (either done at the study center \[during first training sessions and then for every 4th administration\] or at home by the patient or caregiver). The initial weekly dose was determined based on subjects' previous IVIG treatment.
A total of 1570 lesions were evaluated by clinical imaging including X-ray, computed tomography, magnetic resonance imaging and bone scan or PET/CT preoperatively treated with chemotherapy. All patients had surgery in our center and get pathological evaluation by tumor necrosis rate. Statistical diversity analysis was performed by different pathological groups and Receiver Operating Characteristic Curves，ROC were done to find the dividing clinical parameters (Cut-off values) to distinguish different pathological groups.The cut-off values of change rate of maximum diameters of tumor located in extremities were 86%, 50.7% and 0.02% for Huvos Ⅳ,Ⅲ,ⅡandⅠgroups. The differentiation was not obvious using bone scan to distinguish different pathological responses. And the cut-off value for SUVmax value for Huvos Ⅲ,ⅡandⅠgroups were 60.7% and 31.4%.After Multidisciplinary discussion in multiple sites of China, we finally designed a evaluation system based on our data. This study is desgined to prospectively compare the sensitivity and specificity of this Clinical evaluation of primary sarcoma originated from bone with other clinical evaluation system,such as RECIST 1.1, Choi and PERCIST.
The invention belongs to the field of medicines, and particularly relates to application of active substances such as antibody protein, nucleic acid sequence and small molecule inhibitor for reducing activity or expression of CXCL13 protein in preparation of a medicine for treating malignant tumor metastasis. The technical problem to be solved by the invention is to provide a targeted therapeutic scheme of immune regulatory molecules aiming at B cells. The invention provides application of an active substance for reducing the activity or expression quantity of CXCL13 protein in preparing a medicament for treating malignant tumor metastasis. Experiments prove that the CXCL13 blocker or blocking antibody can obviously inhibit lung metastasis of malignant tumor; the CXCL13 blocking agent or blocking antibody combined with chemotherapeutic medicine or T cell immune negative regulator has especially obvious effect of inhibiting malignant tumor lung metastasis. Can receive better synergistic effect. The invention provides a new effective choice for treating the malignant tumor metastasis.
A cosmetic pack composition comprising natural herbs is provided to improve skin softness by moisturizing the skin, prevent skin troubles due to anti-inflammatory, anti-bacterial and skin-calming effects, and inhibit skin wrinkles and enhance skin elasticity by preventing skin aging. A cosmetic pack composition comprises, based on 100 parts by weight of lotus leaf, 90-100 parts by weight of Rhynchosia Nulubilis powder, 60-70 parts by weight of Angelica gigas radix powder, 60-70 parts by weight of Cnidium officinale powder, 60-70 parts by weight of Dioscorea batatas DECNE. powder, 50-60 parts by weight of Kochia scoparia powder, 50-60 parts by weight of Spirodela polyrhiza SCHLEID. powder, 30-40 parts by weight of tangleweed powder, 30-40 parts by weight of Phaseolus radiatus L. powder, 30-40 parts by weight of Glycyrrizae radix powder, 30-40 parts by weight of Coix lachryma-jobi var. ma-yuen powder and 20-30 parts by weight of Lonicera japonica THUNB. powder.
Food allergy is a major cause of life-threatening hypersensitivity reactions. Currently avoidance of the allergenic food is the only established method of preventing reactions in allergic patients. This situation impacts significantly the lives of patients, mainly children, and their families. The current increase in the prevalence of allergic diseases, food allergy in particular, in the Western world has been attributed in part to changes in life style. Before the mid 20th century individuals were exposed to numerous bacterial, parasitic and viral agents. Since these times the progress of hygiene has considerably reduced the risk of exposure to these agents. It is thought that this lack of exposure, particularly during childhood, has led to subtle changes in humans' immune system resulting in an increased propensity to develop allergic and autoimmune responses, the so-called hygiene hypothesis. One of the means of reverting this propensity could be exposure to harmless biological agents. One such agent, eggs of the parasite Trichuris suis (Trichuris suis ova, TSO), has been shown to be well tolerated and efficient in patients with inflammatory bowel diseases. This phase I study will assess whether TSO is safe in adults and children with peanut or tree nut allergy.